- DBV Technologies (DBVT, Financial) has filed an addendum to its 2024 Universal Registration Document with the French market authority, AMF.
- The addendum includes details of exceptional compensation granted to the CEO, requiring shareholder approval at the Annual Combined General Meeting on June 11, 2025.
- The documents are accessible online via DBV Technologies' and the AMF's websites, as well as in printed form at the company's headquarters in Châtillon, France.
DBV Technologies (DBVT), a clinical-stage biopharmaceutical company, has announced the submission of an addendum to its 2024 Universal Registration Document to the French market authority, "Autorité des Marchés Financiers" (AMF). This addendum updates the Corporate Governance Report of the Board of Directors to reflect the exceptional compensation approved for the Chief Executive Officer during the Board meeting on April 30, 2025. Shareholder approval for this compensation is anticipated at the Annual Combined General Meeting on June 11, 2025.
Both the Universal Registration Document and the addendum are available for consultation on the DBV Technologies website and the AMF website. Additionally, printed versions can be obtained at no cost from the company's headquarters located at 107, avenue de la République, 92320 Châtillon, France.
DBV Technologies is known for its innovative approaches to treating food allergies, particularly through its proprietary Viaskin technology platform. The company continues to focus on epicutaneous immunotherapy to address food allergies, aiming to transform patient care by re-educating the immune system to desensitize allergens. The company conducts clinical trials of Viaskin Peanut for peanut allergies in toddlers and children.
